NRF1 and cancer: NRF1 mediates drug resistance in cancer via an oncometabolite, UDP-GlcNAc, which stimulates proteasome subunit genes in response to proteasome inhibitors, before maintaining proteasome activity and protecting cancer cells from proteotoxicity [28].